FDA Warns Selling of Topical CBD Products Violates FD&C Act

On March 22, the U.S. Food and Drug Administration (FDA) stated that it has issued warning letters to two companies for selling topical pain relief products labeled as containing cannabidiol (CBD) in ways that violate the Federal Food, Drug and Cosmetic Act (FD&C Act). Specifically, the warning letters addressed the illegal marketing of unapproved drugs ...